Acasti Pharma, Inc. (ACST) financial statements (2022 and earlier)

Company profile

Business Address 3009, BOUL. DE LA CONCORDE EAST
LAVAL, QC H7E 2B5
State of Incorp. QC
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
3/31/2021
3/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:46,32560,70014,240
Cash and cash equivalents33,01350,94214,240
Short-term investments13,3129,789 
Other undisclosed cash, cash equivalents, and short-term investments (31) 
Receivables238530546
Prepaid expense1,847343977
Deferred costs  121
Disposal group, including discontinued operation587768 
Other current assets  195
Other undisclosed current assets 31 
Total current assets:48,99762,37216,079
Noncurrent Assets
Operating lease, right-of-use asset2286147
Property, plant and equipment  1,910
Intangible assets, net (including goodwill)65,208 4,244
Intangible assets, net (excluding goodwill)65,208 4,244
Other noncurrent assets  473
Total noncurrent assets:65,230866,774
TOTAL ASSETS:114,22762,45822,853
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,8431,4937,319
Accounts payable 1151,713
Accrued liabilities 6074,247
Employee-related liabilities 7711,359
Other undisclosed accounts payable and accrued liabilities2,843  
Derivative instruments and hedges, liabilities32  
Other undisclosed current liabilities228676
Total current liabilities:2,8971,5797,395
Noncurrent Liabilities
Long-term debt and lease obligation  71
Operating lease, liability  71
Liabilities, other than long-term debt2685,2192,393
Derivative instruments and hedges, liabilities2685,2192,393
Total noncurrent liabilities:2685,2192,464
Total liabilities:3,1656,7989,859
Stockholders' equity
Stockholders' equity attributable to parent111,06255,66012,994
Common stock257,990197,194137,424
Additional paid in capital11,53810,8179,797
Accumulated other comprehensive loss(6,533)(6,333)(7,887)
Accumulated deficit(151,933)(146,018)(126,340)
Total stockholders' equity:111,06255,66012,994
TOTAL LIABILITIES AND EQUITY:114,22762,45822,853

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
3/31/2021
3/31/2020
Revenues 196 
Cost of revenue
(Cost of Goods and Services Sold)
 (76) 
Gross profit: 120 
Operating expenses(10,937)(10,836)(24,438)
Other undisclosed operating loss(249)(5,703) 
Operating loss:(11,186)(16,419)(24,438)
Nonoperating income (expense)5,271(3,259)(1,075)
Investment income, nonoperating193107336
Foreign currency transaction gain (loss), before tax172(1,490)(2)
Interest and debt expense  (46)
Loss from continuing operations before equity method investments, income taxes:(5,915)(19,678)(25,559)
Other undisclosed income from continuing operations before income taxes  46
Net loss available to common stockholders, diluted:(5,915)(19,678)(25,513)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
3/31/2021
3/31/2020
Net loss:(5,915)(19,678)(25,513)
Comprehensive loss, net of tax, attributable to parent:(5,915)(19,678)(25,513)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: